Federal Register Notice: FDA has determined the regulatory review period for SDGI Holdings’ Infuse Bone Graft/LT-Cage Lumbar tapered fusion device is 2,052 days for extending patents which claim the medical device. The device is indicated for spinal fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one level from L4—S1. To view this notice, click here.
